Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company announced the presentation of preclinical data for its GABAB positive allosteric modulator cough program at the 10th American Cough Conference [1][2] Company Overview - Addex's lead drug candidate is dipraglurant, a negative allosteric modulator targeting mGlu5, currently under evaluation for brain injury recovery [4] - The company is advancing an independent GABAB PAM program specifically for chronic cough, while also collaborating with Indivior on a GABAB PAM drug candidate for substance use disorders [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [4] Presentation Details - The presentation will be led by Mikhail Kalinichev, Head of Translational Science, discussing the antitussive efficacy of Compound A in guinea pig models [2][3] - The presentation is scheduled for June 7, 2025, at 11:20 am EST [7] Scientific Background - GABAB receptors are crucial in the cough neural circuit and are activated by the neurotransmitter GABA [3] - Current treatments like baclofen have limitations, and targeting allosteric sites may offer advantages such as higher selectivity and better tolerability [3]

Company Expansion - Planisware has opened a new office in Belgium as part of its international expansion strategy in the Benelux region [1][5] - The company has experienced significant growth in the Benelux market, with revenue doubling over the last four years [2] Market Presence - Planisware has been active in the Benelux region for several years, working with major clients such as Galapagos, KLM, Philips, and Engie [2] - The Benelux region is characterized by approximately 1,200 target companies, with nearly half generating annual revenues exceeding one billion euros, particularly in sectors like manufacturing, retail, and financial services [3] Strategic Goals - The new office aims to enhance proximity to customers and local economic players, thereby accelerating new business opportunities and supporting sustainable growth [4] - The CEO emphasized that the expansion into Belgium is a key milestone in the company's growth strategy, reinforcing existing customer relationships and creating local jobs [5] Leadership - The new subsidiary will be led by Benoît Soulier, who has over seven years of project management experience at Planisware and a strong background in managing complex portfolios [5] Company Overview - Planisware is a leading B2B provider of SaaS solutions in the Project Economy, serving around 600 clients across more than 30 countries [6][7]

Core Insights - Burckhardt Compression achieved record financials in fiscal year 2024, surpassing CHF 1 billion in sales and CHF 100 million in net income for the first time, reflecting strong positioning in markets aligned with global megatrends [1][2][3] Financial Performance - Order intake for the Group reached CHF 1,151.2 million, a 2.4% increase, with sales up 12.6% to CHF 1,095.6 million, driven by an 18.2% growth in the Systems Division [2][5] - Gross profit margin improved to 28.0%, up 1.8 percentage points year-on-year, due to a favorable product mix and higher capacity utilization [2] - Consolidated operating income (EBIT) increased by 23.2% to CHF 140.8 million, with an overall Group EBIT margin rising to 12.9% from 11.7% [2][5] Profitability and Returns - Net income reached CHF 105.6 million, exceeding the previous year's figure by 25.0%, with earnings per share rising from CHF 24.98 to CHF 31.20 [3][4] - Return on Net Operating Assets (RONOA) increased from 28.3% to 32.6%, and total equity rose to CHF 340.2 million [4] Dividend Proposal - The Board of Directors proposed a dividend of CHF 18.00 per share, marking a 16.1% increase compared to the previous year, aligning with the Group's attractive dividend policy [4] Market Dynamics - The global Systems market normalized in 2024, with a decrease driven by policy shifts in the Hydrogen Mobility and Energy segment, while demand for Hyper Compressors remained high [5][7] - The Services Division experienced a 5.4% decline in order intake to CHF 325.8 million, influenced by local economic conditions and the closure of low-profit service centers in the US [8] Strategic Initiatives - Burckhardt Compression is implementing its Mid-Range Plan, focusing on strengthening core business, operational excellence, and enhancing business foundations, including a 40.0% reduction in greenhouse gas emission intensity [9][14] - New digital services were launched to optimize compressor fleet reliability and uptime, contributing to the company's transformation efforts [9] Leadership Changes - Upcoming changes in the Board of Directors include the proposal of Jacques Sanche as a new member and Chair, effective December 15, 2025, following Ton Büchner's planned succession [10][11] Guidance for Fiscal Year 2025 - The company expects fiscal year 2025 to maintain sales and EBIT margins at similar levels to fiscal year 2024, amid a dynamic operating environment characterized by uncertainties in global trade and currency exchange rates [12][13]

Core Viewpoint - Helius Medical Technologies, Inc. has announced a public offering of 2,768,600 shares of Class A common stock and accompanying warrants, priced at $3.27 per share, aiming to raise approximately $9.1 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The public offering includes 2,768,600 shares of Class A common stock and warrants to purchase an equal number of shares at a combined price of $3.27 per share [1]. - Each warrant will expire in 2.5 years from issuance, is immediately exercisable at an initial price of $7.3575 per share, and can be exchanged for 2.0 common shares under a zero cash exercise option [2]. - The offering is expected to close on June 6, 2025, subject to customary closing conditions [3]. Group 2: Regulatory and Contact Information - A registration statement on Form S-1 was filed with the SEC and declared effective on June 4, 2025, with a final prospectus to be available on the SEC's website [4]. - Electronic copies of the prospectus can be obtained from Maxim Group LLC, the sole placement agent for the offering [4][7].

Core Points - Vortex Energy Corp. has announced the conversion of outstanding unsecured convertible debentures following notices of conversion from all holders [1] - The company issued the debentures on January 28, 2025, for a total principal amount of C$400,000, with accrued interest resulting in a total payable amount of C$413,916.36 [2] - To satisfy this amount, Vortex will issue 1,061,324 units at a conversion price of C$0.39 per unit, each unit consisting of one common share and one warrant [3] Company Overview - Vortex Energy Corp. is engaged in the acquisition, exploration, and development of mineral properties in North America, focusing on the Robinson River Salt Project and the Fire Eye Uranium Property [5]

Group 1 - BitMine Immersion Technologies, Inc. announced a public offering of 2,250,000 shares at $8.00 per share, aiming for gross proceeds of $18 million before expenses [1] - The company has received approval for listing on the NYSE American, with trading expected to start on June 5, 2025, under the symbol "BMNR" [2] - The net proceeds from the offering will be used to purchase bitcoin [3] Group 2 - A registration statement for the offering was filed with the SEC and became effective on June 4, 2025 [4] - The offering is managed by ThinkEquity, which is acting as the sole book-running manager [3] - BitMine operates in low-cost energy regions, focusing on bitcoin mining and advisory services [6]

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- BWR Exploration Inc. (BWR.V TSX.V) (“BWR”), is pleased to announce that as per the previously announced Bridge Financing regarding a proposed business combination with Electro Metals and Mining Inc. (“Electro”), a federally registered private company, both companies have raised $240,000, surpassing the minimum aggregate amount needed as a condition of the proposed business combination as announced on December 27, 2024. Private Placements It was a condition of compl ...

Core Viewpoint - Alvotech has successfully completed a private placement of 7,500,000 shares, raising gross proceeds of SEK 750 million, with strong interest from institutional investors, particularly from Sweden and other international markets [2][4][5]. Group 1: Placement Details - The private placement included 5,833,500 Swedish Depository Receipts (SDRs) and 1,666,500 ordinary shares, priced at SEK 100.00 per SDR and ISK 1320.83 per ordinary share, reflecting current market conditions [3][5]. - The transaction was facilitated by DNB Carnegie and Citi as Joint Global Coordinators and Joint Bookrunners, with SEB and ACRO also participating as Joint Bookrunners [2][3][13]. - Settlement of the placement is expected around June 10, 2025, for both SDRs and ordinary shares [8]. Group 2: Use of Proceeds - The net proceeds from the placement will be allocated to upscale R&D efforts, particularly in Sweden, following the acquisition of Xbrane's R&D operations, and to capitalize on growth opportunities [5][7]. - The funds will also be used for general corporate purposes, enhancing the company's market position [5]. Group 3: Shareholder Base and Market Impact - The placement is expected to diversify and strengthen Alvotech's shareholder base, particularly among institutional investors in Sweden, and significantly increase the float of SDRs on Nasdaq Stockholm [7]. - The strong interest from institutional investors indicates the importance of the SDR listing on Nasdaq Stockholm for the company's growth strategy [4][7].

Core Viewpoint - The acceptance of the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for treating advanced renal cell carcinoma in China represents a significant advancement in addressing unmet medical needs in this patient population [1][3]. Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [16]. - Innovent Biologics is a leading biopharmaceutical company dedicated to providing affordable, high-quality biopharmaceuticals, with a focus on innovative medicines for various diseases, including cancer [17]. Product Information - Fruquintinib is a selective oral inhibitor targeting all three vascular endothelial growth factor receptors (VEGFR) and is designed to inhibit tumor angiogenesis effectively [5]. - Sintilimab, marketed as TYVYT, is a PD-1 monoclonal antibody that reactivates T-cells to combat cancer by blocking the PD-1/PD-L1 pathway [11]. Clinical Study Insights - The NDA is supported by data from the FRUSICA-2 study, which demonstrated that the combination of fruquintinib and sintilimab met its primary endpoint of progression-free survival (PFS) and showed improvements in secondary endpoints such as objective response rate (ORR) and duration of response (DoR) [2][3]. - In a proof-of-concept Phase Ib/II study, the combination therapy showed a confirmed ORR of 60.0% and a disease control rate (DCR) of 85.0%, with a median PFS of 15.9 months [10]. Market Context - Kidney cancer poses significant challenges in China, with approximately 74,000 new cases diagnosed in 2022, and renal cell carcinoma accounts for about 90% of kidney tumors [4]. - The combination therapy aims to provide a more effective second-line treatment option for patients who have failed prior treatments with tyrosine kinase inhibitors (TKIs) [3][9]. Regulatory Milestones - The combination of fruquintinib and sintilimab previously received conditional approval for treating advanced mismatch repair proficient (pMMR) endometrial cancer in December 2024, indicating the ongoing regulatory progress for these therapies [3][7].

VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE:MEC, OTC:MECPF, FRA:92T) (“Mustang” or the “Company”) is excited to announce that it has entered into two strategic option agreements with Thunderbird Resources Ltd. (“Thunderbird”) to acquire an undivided 80% interest in certain mineral tenements held by Thunderbird located in the Athabasca Basin of Northern Saskatchewan (the “Project”). The Option marks an important step for Mustang as it continues to expand and build ...